Format

Send to

Choose Destination
PLoS One. 2013 Nov 26;8(11):e81345. doi: 10.1371/journal.pone.0081345. eCollection 2013.

Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.

Author information

1
Department of Pharmacology, College of Pharmaceutical Sciences, Cyrus Tang Hematology Center, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu, China.

Abstract

BACKGROUND:

Glioblastoma multiforme (GBM), the most common form of brain cancer with an average survival of less than 12 months, is a highly aggressive and fatal disease characterized by survival of glioma cells following initial treatment, invasion through the brain parenchyma and destruction of normal brain tissues, and ultimately resistance to current treatments. Temozolomide (TMZ) is commonly used chemotherapy for treatment of primary and recurrent high-grade gliomas. Nevertheless, the therapeutic outcome of TMZ is often unsatisfactory. In this study, we sought to determine whether eEF-2 kinase affected the sensitivity of glioma cells to treatment with TMZ.

METHODOLOGY/PRINCIPAL FINDINGS:

Using RNA interference approach, a small molecule inhibitor of eEF-2 kinase, and in vitro and in vivo glioma models, we observed that inhibition of eEF-2 kinase could enhance sensitivity of glioma cells to TMZ, and that this sensitizing effect was associated with blockade of autophagy and augmentation of apoptosis caused by TMZ.

CONCLUSIONS/SIGNIFICANCE:

These findings demonstrated that targeting eEF-2 kinase can enhance the anti-glioma activity of TMZ, and inhibitors of this kinase may be exploited as chemo-sensitizers for TMZ in treatment of malignant glioma.

PMID:
24303044
PMCID:
PMC3841121
DOI:
10.1371/journal.pone.0081345
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center